U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000092: PROMIS® Pediatric Crohn’s Disease Short Form - Fatigue 10
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000092: PROMIS® Pediatric Crohn’s Disease Short Form - Fatigue 10

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Immunology and Inflammation (OII)
Division of Gastroenterology (DG)

DDT COA Number
DDT COA #000092

Instrument Name
PROMIS® Pediatric Crohn’s Disease Short Form - Fatigue 10

Disease/Condition
Crohn’s disease (CD)

Concept of Interest
Fatigue (frequency, duration and intensity)

Context of Use
Children (8-17 years) with CD

COA Type
PRO

Qualification Stage
Letter of Intent - Accepted

Requestor(s)
Anthony Otley

Contact(s)
Carole Tucker
Christopher Forrest

Date Accepted into CDER’s COA Qualification Program
July 11, 2017

Submission and Regulatory Correspondence History

Qualification Submission Date FDA Submission Decision & Recommendations Date
Letter of Intent 1/31/17 FDA Response (Accepted) 7/11/2017
Back to Top